CORE
CO
nnecting
RE
positories
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Research partnership
About
About
About us
Our mission
Team
Blog
FAQs
Contact us
Community governance
Governance
Advisory Board
Board of supporters
Research network
Innovations
Our research
Labs
Filters
1 research outputs found
Lifetime Health Consequences and Cost-effectiveness of Rosiglitazone in Combination with Metformin for the Treatment of Type 2 Diabetes in Spain
Author
A Bagust
A Bagust
+52 more
A Bagust
A Dominguez-Gil
A Goday
A Rodriguez-Carmona
A Shearer
Adrian Bagust
AJ Palmer
Arran T. Shearer
Belén Martínez-Lage Álvarez
CB Rodríguez
CJ Currie
CMBD Insalud
D Kirpichnikov
E Esmatjes
F Carrl
F. Javier Ampudia-Blasco
Farmaindustria
Gonzalo París
Heart Protection Study Collaborative Group
HM Colhoun
IMS
International Diabetes Federation
Isabel Pérez Escolano
IW Campbell
J Cabezas-Cerrato
J Oliva
JA Sacristan
JA Velasco
JA Vázquez
JB Brown
JJ Nolan
JL Clua Espuny
JM Arteagoitia
K Hallsten
K Hällsten
KA Virtanen
KA Virtanen
KM Anderson
M Mata
MF Drummond
MR Gold
R Gisbert
R Klein
RA Fronzo De
RC Eastman
RC Eastman
RJ Stevens
S Beale
Taylor Nelson Sofres Healthcare S.A. (Spain)
Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice
V Kothari
V Ortún
Publication venue
'Springer Science and Business Media LLC'
Publication date
Field of study
No full text
Crossref
No full text
